Evidence map›Paper›PMID 36960537›Full record

ArticleTechnology in cancer research & treatment

Evaluation of Radiation Sensitivity Differences in Mouse Liver Tumor Organoids Using CRISPR/Cas9-Mediated Gene Mutation.

Wan Jeon, Se Yeon Jung, Chae Young Lee, Won-Tae Kim, Hyun Kim, Kyoung Won Jang, Heuijin Lim, Manwoo Lee, Dong Hyeok Jeong, Sung Dae Kim and 4 more

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. CRISPR/Cas9 systems: Delivery technologies and biomedical applications.Asian journal of pharmaceutical sciences · 2023
    Review
  3. Human enteroids as a tool to study conventional and ultra-high dose rate radiation.Integrative biology : quantitative biosciences from nano to macro · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Wan JeonDepartment of Radiation Oncology, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.ORCID 0000-0002-0849-8312
Se Yeon JungResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Chae Young LeeResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Won-Tae KimResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Hyun KimResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Kyoung Won JangResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Heuijin LimResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Manwoo LeeResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Dong Hyeok JeongResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Sung Dae KimResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
In Ah KimDepartment of Radiation Oncology, 37990Seoul National University College of Medicine, Seoul, Republic of Korea.
Si Ho ChoiResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Tae Gen SonResearch Center, 222204Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea.
Kyung Su KimDepartment of Radiation Oncology, 37990Seoul National University College of Medicine, Seoul, Republic of Korea.
Dongnam Institute of Radiological & Medical Sciences · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess the radiosensitivity of liver tumors harboring different genetic mutations, mouse liver tumors were generated in vivo through the hydrodynamic injection of clustered regularly interspaced short palindromic repeat/caspase 9 (CRISPR/Cas9) constructs encoding single-guide RNAs (sgRNAs) targeting

methodsThe plasmid vectors were delivered to the liver of adult C57BL/6 mice via hydrodynamic tail vein injection. The vectors were injected into 10 mice in each group. Organoids were generated from mouse liver tumors. The radiation response of the organoids was assessed using an ATP cell viability assay.

resultsThe mean survival period of mice injected with vectors targeting

conclusionsThis study developed a radiation response assessment system for mouse tumors with mutant target genes using CRISPR/Cas9 and organoids. The

Indexed as

CRISPR-Cas SystemsLiver NeoplasmsAdenosine TriphosphateAnimalsMiceMice, Inbred C57BLMutationOrganoidsAdenosine TriphosphateCRISPR-Cas systemsliverorganoidsradiation tolerancetumor

Identifiers

PMID36960537
PMCPMC10041602
OpenAlexW4360810249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.